Hypothyroidism is a common clinical entity which is often complicated by dyslipidemia. It is also reported increased risk for incidence of atherosclerosis and resulting coronary heart disease(CHD), heart failure(HF) and cardiovascular(CV) death. The effect of L-thyroxine replacement treatment on serum lipid and atherosclerosis is controversial in hypothyroid patients, especially in those with mild or moderate subclinical hypothyroidism. The present study was designed to investigate whether L-thyroxine replacement was effective in improving serum lipid profiles and retarding atherosclerosis progress. Studies have shown that hypothyroidism increased the risk of COVID-19 composite poor outcomes. This study also aimed to investigate whether L-thyroxine replacement therapy was effective in reducing the incidence and mortality of COVID-19, and in improving the severity of COVID-19 and COVID-19 related complications.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
700
Shandong Provincial Hospital
Jinan, Shandong, China
Rate of First cardiovascular disorder (CVD) Events, CVD Mortality and All-cause Mortality
Time frame: endpoint of the trail
Change in Serum Lipid Levels
Time frame: baseline, 3 months, 6 months, every 12 months during the following follow-up period until the trial is completed
Change in Thickness of Blood Vessel Wall
Time frame: baseline, 3 months, 6 months, every 12 months during the following follow-up period until the trial is completed
Change in Oxidative Stress and Chronic Inflammatory Factors Associated with Atherosclerosis
Time frame: baseline, 3 months, 6 months, every 12 months during the following follow-up period until the trail is completed
Changes in Serum Metabolome and Lipidome
Time frame: baseline, 3 months, 6 months, every 12 months during the following follow-up period until the trail is completed
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.